Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and ...
PVP Labs, a biotechnology company advancing next-generation peptide-based therapeutics, today announced its participation in the JP Morgan Healthcare Conference 2026, where the company will engage ...
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...
Around 30% of organisations report that 20–40% of their work in HR and IT or admin is now handled through AI, helping manage ...
A live webcast and replay of the session will be available on the Company’s Investor Relations website at https://defidevcorp.com/investor?tab=media-events. To register for the webcast, please visit: ...
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today ...
Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® ...
PALO ALTO, CA, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- TuxCare, a global innovator in securing open ...
Ceva, Inc. (NASDAQ: CEVA), the leading licensor of silicon and software IP for the Smart Edge, will announce results for the fourth quarter and full year 2025 on February 17, 2026 before the NASDAQ ...
Early iOS 27 rumors hint at a surprising shift in Apple’s strategy that could change how your iPhone feels in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback